Content
April 2019, Volume 37, Issue 4
- 513-530 Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England
by Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell - 531-540 The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment
by Renske J. Hoefman & Job Exel & Werner B. F. Brouwer - 541-551 Parent Preferences for Health Outcomes Associated with Autism Spectrum Disorders
by Tara A. Lavelle & Milton C. Weinstein & Joseph P. Newhouse & Kerim Munir & Karen A. Kuhlthau & Lisa A. Prosser - 553-562 Economic Spillover Effects of Intensive Unpaid Caregiving
by Josephine C. Jacobs & Courtney H. Van Houtven & Terri Tanielian & Rajeev Ramchand - 563-572 Dementia Family Caregivers’ Willingness to Pay for an In-home Program to Reduce Behavioral Symptoms and Caregiver Stress
by Eric Jutkowitz & Danny Scerpella & Laura T. Pizzi & Katherine Marx & Quincy Samus & Catherine Verrier Piersol & Laura N. Gitlin - 573-583 Close-Person Spill-Overs in End-of-Life Care: Using Hierarchical Mapping to Identify Whose Outcomes to Include in Economic Evaluations
by Alastair Canaway & Hareth Al-Janabi & Philip Kinghorn & Cara Bailey & Joanna Coast - 585-596 An Examination of Downstream Effects of Bereavement on Healthcare Utilization for Surviving Spouses in a National Sample of Older Adults
by Katherine A. Ornstein & Melissa M. Garrido & Albert L. Siu & Evan Bollens-Lund & Omari-Khalid Rahman & Amy S. Kelley - 597-608 Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer’s Disease Interventions
by Pei-Jung Lin & Brittany D’Cruz & Ashley A. Leech & Peter J. Neumann & Myrlene Sanon Aigbogun & Dorothee Oberdhan & Tara A. Lavelle - 609-620 Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D
by Clare C. Brown & J. Mick Tilford & Nalin Payakachat & D. Keith Williams & Karen A. Kuhlthau & Jeffrey M. Pyne & Renske J. Hoefman & Werner B. F. Brouwer - 621-623 The Inclusion of Spillover Effects in Economic Evaluation: A Public Health Economics Perspective
by Rhiannon Tudor Edwards - 625-625 Correction to: Parental Health Spillover in Cost‑Effectiveness Analysis: Evidence from Self‑Harming Adolescents in England
by Sandy Tubeuf & Eirini-Christina Saloniki & David Cottrell
March 2019, Volume 37, Issue 3
- 293-299 Determining Value in Health Technology Assessment: Stay the Course or Tack Away?
by J. Jaime Caro & John E. Brazier & Jonathan Karnon & Peter Kolominsky-Rabas & Alistair J. McGuire & Erik Nord & Michael Schlander - 301-331 Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review
by Chun-Ru Chien & Daniel M. Geynisman & Bumyang Kim & Ying Xu & Ya-Chen Tina Shih - 333-343 Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Emma Simpson & Jean Hamilton & Daniel Pollard & Mark Clowes & Eva Kaltenthaler & David Meiklejohn & Nick Morley - 345-357 Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Tosin Lambe & Rui Duarte & James Mahon & Sarah Nevitt & Janette Greenhalgh & Angela Boland & Sophie Beale & Eleanor Kotas & Joanne McEntee & Ian Pomeroy - 359-389 Evaluating Cost-Effectiveness Models for Pharmacologic Interventions in Adults with Heart Failure: A Systematic Literature Review
by Gian Luca Di Tanna & Anna Bychenkova & Frank O’Neill & Heidi S. Wirtz & Paul Miller & Briain Ó Hartaigh & Gary Globe - 391-405 Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
by Holly Guy & Lydia Walder & Mark Fisher - 407-417 Measuring Public Preferences for Health Outcomes and Expenditures in a Context of Healthcare Resource Re-Allocation
by Nicolas Krucien & Nathalie Pelletier-Fleury & Amiram Gafni - 419-433 Opioid Use is Associated with Higher Severity-Adjusted Episode Costs in Patients with Conservatively Managed Degenerative Joint Disease of the Back and Neck
by Brent A. Metfessel & Michelle D. Mentel & Amy Phanel & Mary Ann Dimartino & Mureen Allen & Samuel Ho - 435-446 Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis
by Emma Warren & Kristen Morgan & Toby J. Toward & Matthias Schwenkglenks & Joanna Leadbetter
February 2019, Volume 37, Issue 2
- 119-130 Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
by Linda M. Vries & Pieter H. M. Baal & Werner B. F. Brouwer - 131-139 Brodalumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Ros Wade & Alessandro Grosso & Emily South & Claire Rothery & Pedro Saramago & Laetitia Schmitt & Kath Wright & Stephen Palmer - 141-153 Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Saskia Groot & Rob Riemsma & Debra Fayter & Nigel Armstrong & Piet Portegijs & Steven Duffy & Jos Kleijnen & Maiwenn J. Al - 155-167 The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence
by Richard Perry & George Braileanu & Thomas Palmer & Paul Stevens - 169-200 Cost-Effectiveness of Herpes Zoster Vaccination: A Systematic Review
by Edward T. Chiyaka & Van T. Nghiem & Lu Zhang & Abhishek Deshpande & Patricia Dolan Mullen & Phuc Le - 201-226 Discrete Choice Experiments in Health Economics: Past, Present and Future
by Vikas Soekhai & Esther W. Bekker-Grob & Alan R. Ellis & Caroline M. Vass - 227-238 Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis
by Tracey-Lea Laba & Helen K. Reddel & Nicholas J. Zwar & Guy B. Marks & Elizabeth Roughead & Anthony Flynn & Michele Goldman & Aine Heaney & Kirsty Lembke & Stephen Jan - 239-253 Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States
by Eytan Stein & Jipan Xie & Emilie Duchesneau & Subrata Bhattacharyya & Umakanth Vudumula & Briana Ndife & Gaetano Bonifacio & Annie Guerin & Nanxin Li & George Joseph - 255-266 Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data
by Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini - 267-278 Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand
by Bunchai Chongmelaxme & Pochamana Phisalprapa & Ratree Sawangjit & Piyameth Dilokthornsakul & Nathorn Chaiyakunapruk - 279-289 Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding
by Thananan Rattanachotphanit & Chulaporn Limwattananon & Onanong Waleekhachonloet & Phumtham Limwattananon & Kittisak Sawanyawisuth - 291-291 Correction to: Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-alcoholic Fatty Liver Disease in Thailand
by Bunchai Chongmelaxme & Pochamana Phisalprapa & Ratree Manthaisong & Piyameth Dilokthornsakul & Nathorn Chaiyakunapruk
January 2019, Volume 37, Issue 1
- 1-6 Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?
by Salah Ghabri & Matt Stevenson & Jörgen Möller & J. Jaime Caro - 7-18 Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Paul Tappenden & Christopher Carroll & John Stevens & Emma Simpson & Praveen Thokala & Ruth Wong & Josh Wright & Rebecca Auer - 19-27 Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Daniel Gallacher & Xavier Armoiry & Peter Auguste & Rachel Court & Theodoros Mantopoulos & Jacoby Patterson & Maria Santis & Joanne Cresswell & Hema Mistry - 29-43 One Method, Many Methodological Choices: A Structured Review of Discrete-Choice Experiments for Health State Valuation
by Brendan Mulhern & Richard Norman & Deborah J. Street & Rosalie Viney - 45-61 Systematic Literature Review of the Economic Burden of Celiac Disease
by Elizabeth S. Mearns & Aliki Taylor & Talia Boulanger & Kelly J. Craig & Michele Gerber & Daniel A. Leffler & Jennifer Drahos & David S. Sanders & Benjamin Lebwohl - 63-74 Exploring Different Strategies of Assessing the Economic Impact of Multiple Diabetes-Associated Complications and Their Interactions: A Large Claims-Based Study in Germany
by Katharina Kähm & Michael Laxy & Udo Schneider & Rolf Holle - 75-84 The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals
by Becky Pennington & Monica Hernandez-Alava & Stephen Pudney & Allan Wailoo - 85-92 Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study
by Namita Joshi & Marja Hensen & Sachin Patel & Weiwei Xu & Kathy Lasch & Elly Stolk - 93-103 Estimating Informal Caregiving Time from Patient EQ-5D Data: The Informal CARE Effect (iCARE) Tool
by Maria Gheorghe & Renske J. Hoefman & Matthijs M. Versteegh & Job Exel - 105-116 Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
by Min Huang & M. Catherine Pietanza & Ayman Samkari & James Pellissier & Thomas Burke & Sheenu Chandwani & Fansen Kong & A. Simon Pickard - 117-117 Correction to: The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
by James Love-Koh & Alison Peel & Juan Carlos Rejon-Parrilla & Kate Ennis & Rosemary Lovett & Andrea Manca & Anastasia Chalkidou & Hannah Wood & Matthew Taylor
December 2018, Volume 36, Issue 12
- 1395-1405 Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues
by Patricia M. Danzon - 1407-1420 Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?
by Jorge Mestre-Ferrandiz & Néboa Zozaya & Bleric Alcalá & Álvaro Hidalgo-Vega - 1421-1426 Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models
by Anthony J. Hatswell & Ash Bullement & Andrew Briggs & Mike Paulden & Matthew D. Stevenson - 1427-1437 Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Shijie Ren & Emma Simpson & Mark Clowes & David L. Scott & Adam Young & Matt Stevenson - 1439-1451 The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
by James Love-Koh & Alison Peel & Juan Carlos Rejon-Parrilla & Kate Ennis & Rosemary Lovett & Andrea Manca & Anastasia Chalkidou & Hannah Wood & Matthew Taylor - 1453-1462 Understanding and Identifying Key Issues with the Involvement of Clinicians in the Development of Decision-Analytic Model Structures: A Qualitative Study
by Samantha Husbands & Susan Jowett & Pelham Barton & Joanna Coast - 1463-1473 Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
by Mark Bounthavong & Javed Butler & Chantal M. Dolan & Jeffrey D. Dunn & Kathryn A. Fisher & Nina Oestreicher & Bertram Pitt & Paul J. Hauptman & David L. Veenstra - 1475-1490 Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea
by Yun-Kyung Kim & Joon Young Song & Hyeongap Jang & Tae Hyun Kim & Heejo Koo & Lijoy Varghese & Euna Han
November 2018, Volume 36, Issue 11
- 1299-1308 Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
by Micah Rose & Jonathan Shepherd & Petra Harris & Karen Pickett & Joanne Lord - 1309-1319 Model Structuring for Economic Evaluations of New Health Technologies
by Hossein Haji Ali Afzali & Laura Bojke & Jonathan Karnon - 1321-1331 Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis
by Jean-Hugues Salmon & Anne-Christine Rat & Isabelle Charlot-Lambrecht & Jean-Paul Eschard & Damien Jolly & Bruno Fautrel - 1333-1343 Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
by Mahdi Gharaibeh & Ali McBride & David S. Alberts & Brian Erstad & Marion Slack & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham - 1345-1353 Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L
by Anna Hobbins & Luke Barry & Dan Kelleher & Koonal Shah & Nancy Devlin & Juan Manuel Ramos Goni & Ciaran O’Neill - 1355-1365 Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients
by Kristina R. Dahlstrom & Shuangshuang Fu & Wenyaw Chan & Zeena Shelal & Lois M. Ramondetta & David R. Lairson - 1367-1376 Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case–Control Study in Japan
by Haruhisa Fukuda & Takahisa Yano & Nobuyuki Shimono - 1377-1389 Severity-Stratified Discrete Choice Experiment Designs for Health State Evaluations
by Sesil Lim & Marcel F. Jonker & Mark Oppe & Bas Donkers & Elly Stolk
October 2018, Volume 36, Issue 10
- 1135-1141 Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?
by John W. Stevens - 1143-1151 Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Rachid Rafia & Abdullah Pandor & Sarah Davis & John W. Stevens & Sue Harnan & Mark Clowes & Youssef Sorour & Robert Cutting - 1153-1163 Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Angela Stainthorpe & Janette Greenhalgh & Adrian Bagust & Marty Richardson & Angela Boland & Sophie Beale & Rui Duarte & Eleanor Kotas & Lindsay Banks & Daniel Palmer - 1165-1200 Cost Effectiveness of Pharmacological Treatments for Asthma: A Systematic Review
by Carlos E. Rodriguez-Martinez & Monica P. Sossa-Briceño & Jose A. Castro-Rodriguez - 1201-1222 Costs of Invasive Meningococcal Disease: A Global Systematic Review
by Bing Wang & Renee Santoreneos & Hossein Afzali & Lynne Giles & Helen Marshall - 1223-1252 Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations
by Luis Hernandez & Malinda O’Donnell & Maarten Postma - 1253-1261 Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis
by Jesse Elliott & Bláthnaid McCoy & Tammy Clifford & George A. Wells & Doug Coyle - 1263-1272 The Impact of Hospital Costing Methods on Cost-Effectiveness Analysis: A Case Study
by José Leal & Stefania Manetti & James Buchanan - 1273-1284 Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer
by Mahdi Gharaibeh & Ali McBride & David S. Alberts & Marion Slack & Brian Erstad & Nimer Alsaid & J. Lyle Bootman & Ivo Abraham - 1285-1296 Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
by Afschin Gandjour & Dennis A. Ostwald - 1297-1297 Comment on: Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & James Carpenter
September 2018, Volume 36, Issue 9
- 1031-1041 Are PCSK9 Inhibitors Cost Effective?
by Max J. Korman & Kjetil Retterstøl & Ivar Sønbø Kristiansen & Torbjørn Wisløff - 1043-1061 A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values
by Stavros Petrou & Joseph Kwon & Jason Madan - 1063-1072 Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Lesley Uttley & Iñigo Bermejo & Shijie Ren & Marrissa Martyn-St James & Ruth Wong & David L. Scott & Adam Young & Matt Stevenson - 1073-1081 Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
by Xavier Armoiry & Martin Connock & Alexander Tsertsvadze & Ewen Cummins & G. J. Melendez-Torres & Pam Royle & Aileen Clarke - 1083-1092 Review of Economic Value Drivers of the Treatment of Overactive Bladder
by Sonya J. Snedecor - 1093-1099 Estimating Drug Costs: How do Manufacturer Net Prices Compare with Other Common US Price References?
by T. Joseph Mattingly & Joseph F. Levy & Julia F. Slejko & Nneka C. Onwudiwe & Eleanor M. Perfetto - 1101-1112 Smoking Cessation: A Comparison of Two Model Structures
by Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor - 1113-1124 Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor–positive and Human Epidermal Growth Factor Receptor 2–negative Metastatic Breast Cancer in Japan
by Verin Lertjanyakun & Nathorn Chaiyakunapruk & Susumu Kunisawa & Yuichi Imanaka - 1125-1134 Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO)
by Hui Shao & Vivian Fonseca & Charles Stoecker & Shuqian Liu & Lizheng Shi
August 2018, Volume 36, Issue 8
- 883-888 Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation
by Feng Xie - 889-901 Sensitivity Analysis for Not-at-Random Missing Data in Trial-Based Cost-Effectiveness Analysis: A Tutorial
by Baptiste Leurent & Manuel Gomes & Rita Faria & Stephen Morris & Richard Grieve & James R. Carpenter - 903-915 Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Abdullah Pandor & Matt Stevenson & John Stevens & Marrissa Martyn-St James & Jean Hamilton & Jenny Byrne & Claudius Rudin & Andrew Rawdin & Ruth Wong - 917-927 Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Robert F. Wolff & Xavier Pouwels & Marije Oosterhoff & Anoukh Giessen & Gill Worthy & Caro Noake & Nigel Armstrong & Jos Kleijnen & Manuela A. Joore - 929-939 Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence
by Didik Setiawan & Abrham Wondimu & KohJun Ong & Albert Jan Hoek & Maarten J. Postma - 941-955 Does Non-Adherence Increase Treatment Costs in Schizophrenia?
by Mark Pennington & Paul McCrone - 957-971 Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations
by R. Brett McQueen & Danielle N. Sheehan & Melanie D. Whittington & Job F. M. Boven & Jonathan D. Campbell - 973-986 Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment
by Juan Marcos González & Justin Doan & David J. Gebben & Marco Boeri & Mayer Fishman - 987-994 Applying GRADE Criteria to Clinical Inputs to Cost-Effectiveness Modeling Studies
by Alexander Mensch & Tanja Beck & Daniele Civello & Christopher Kunigkeit & Nicole Lachmann & Stephanie Stock & Afschin Gandjour & Dirk Müller - 995-1004 Effects of County Public Hospital Reform on Procurement Costs and Volume of Antibiotics: A Quasi-Natural Experiment in Hubei Province, China
by Yuqing Tang & Chaojie Liu & Junjie Liu & Xinping Zhang & Keyuan Zuo - 1005-1013 Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors
by Chan Shen & Arvind Dasari & Dian Gu & Yiyi Chu & Shouhao Zhou & Ying Xu & Daniel Halperin & Shuangshuang Fu & James C. Yao & Ya-Chen Tina Shih - 1015-1027 Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
by Paul Emery & Marjolijn Keep & Steve Beard & Chris Graham & LaStella Miles & Steffen Marc Jugl & Praveen Gunda & Anna Halliday & Helena Marzo-Ortega - 1029-1029 Comment on: “Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales Onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children”
by Emma Frew & Tosin Lambe
July 2018, Volume 36, Issue 7
- 731-732 Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in ‘Rich’ Countries?
by Alan Haycox - 733-743 Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?
by Fernando Antoñanzas & Roberto Rodríguez-Ibeas & Carmelo A. Juárez-Castelló - 745-758 Discounting in Economic Evaluations
by Arthur E. Attema & Werner B. F. Brouwer & Karl Claxton - 759-768 Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Matt Stevenson & Abdullah Pandor & Jean Hamilton & John Stevens & Clare Rowntree & Marrissa Martyn-St James & Andrew Rawdin & Ruth Wong - 769-778 Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Shijie Ren & Iñigo Bermejo & Emma Simpson & Ruth Wong & David L. Scott & Adam Young & Matt Stevenson - 779-807 The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
by Alex Diamantopoulos & Emily Wright & Katerina Vlahopoulou & Laura Cornic & Nils Schoof & Toby M. Maher - 809-822 Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
by Guy Neff & Woodie Zachry III - 823-835 The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests
by Alison F. Smith & Mike Messenger & Peter Hall & Claire Hulme - 837-851 Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
by Irina A. Tikhonova & Nicola Huxley & Tristan Snowsill & Louise Crathorne & Jo Varley-Campbell & Mark Napier & Martin Hoyle - 853-865 Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
by Przemysław Holko & Paweł Kawalec & Andrzej Pilc - 867-878 Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
by Vanessa Buchanan & Will Sullivan & Chris Graham & LaStella Miles & Steffen Marc Jugl & Praveen Gunda & Anna Halliday & Bruce Kirkham - 879-879 Comment on: “A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis”
by Ena Singh - 881-881 Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
by Guy Neff & Woodie Zachry
June 2018, Volume 36, Issue 6
- 637-640 3L, 5L, What the L? A NICE Conundrum
by Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk - 641-643 Once Bitten Twice Shy: Thinking Carefully Before Adopting the EQ-5D-5L
by Jeff Round - 645-661 A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D
by Ines Buchholz & Mathieu F. Janssen & Thomas Kohlmann & You-Shan Feng - 663-674 German Value Set for the EQ-5D-5L
by Kristina Ludwig & J.-Matthias Graf von der Schulenburg & Wolfgang Greiner - 675-697 Is EQ-5D-5L Better Than EQ-5D-3L? A Head-to-Head Comparison of Descriptive Systems and Value Sets from Seven Countries
by Mathieu F. Janssen & Gouke J. Bonsel & Nan Luo - 699-713 Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
by Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin - 715-725 Head-to-Head Comparison of EQ‐5D‐3L and EQ‐5D‐5L Health Values
by Anna Selivanova & Erik Buskens & Paul F. M. Krabbe - 727-727 Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets
by Brendan Mulhern & Yan Feng & Koonal Shah & Mathieu F. Janssen & Michael Herdman & Ben Hout & Nancy Devlin - 729-729 Correction to: 3L, 5L, What the L? A NICE Conundrum
by Nancy Devlin & John Brazier & A. Simon Pickard & Elly Stolk
May 2018, Volume 36, Issue 5
- 509-522 Cost-Effectiveness Thresholds: the Past, the Present and the Future
by Praveen Thokala & Jessica Ochalek & Ashley A. Leech & Thaison Tong - 523-532 Different Methods for Modelling Severe Hypoglycaemic Events: Implications for Effectiveness, Costs and Health Utilities
by Edna Keeney & Dalia Dawoud & Sofia Dias - 533-543 Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Xavier G. L. V. Pouwels & Robert Wolff & Bram L. T. Ramaekers & Anoukh Giessen & Shona Lang & Steve Ryder & Gill Worthy & Steven Duffy & Nigel Armstrong & Jos Kleijnen & Manuela A. Joore - 545-553 Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Keith Cooper & Geoff Frampton & Petra Harris & Micah Rose & Maria Chorozoglou & Karen Pickett - 555-565 The Australian Managed Entry Scheme: Are We Getting it Right?
by Haitham W. Tuffaha & Paul A. Scuffham - 567-589 Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review
by Lucia Sara D’Angiolella & Paolo Angelo Cortesi & Alessandra Lafranconi & Mariangela Micale & Sveva Mangano & Giancarlo Cesana & Lorenzo Giovanni Mantovani - 591-601 Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
by Torbjørn Wisløff & Richard White & Olav Dalgard & Ellen J. Amundsen & Hinta Meijerink & Astrid Louise Løvlie & Hilde Kløvstad - 603-612 A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet
by Björn Stollenwerk & Sergio Iannazzo & Ron Akehurst & Michael Adena & Andrew Briggs & Bastian Dehmel & Patrick Parfrey & Vasily Belozeroff - 613-624 New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes
by Alice Varnava & Robert Bracchi & Karen Samuels & Dyfrig A. Hughes & Philip A. Routledge - 625-636 Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy
by M. Ruggeri & M. Basile & C. Drago & F. R. Rolli & A. Cicchetti
April 2018, Volume 36, Issue 4
- 385-386 Is ICER NICEr?
by Deborah Freund & Jennifer Choi - 387-398 Ustekinumab for Treating Moderately to Severely Active Crohn’s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Robert Hodgson & Matthew Walton & Mousumi Biswas & Teumzghi Mebrahtu & Nerys Woolacott - 399-406 Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hema Mistry & Chidozie Nduka & Martin Connock & Jill Colquitt & Theodoros Mantopoulos & Emma Loveman & Renata Walewska & James Mason - 407-417 The French National Authority for Health (HAS) Guidelines for Conducting Budget Impact Analyses (BIA)
by Salah Ghabri & Erwan Autin & Anne-Isabelle Poullié & Jean Michel Josselin - 419-434 A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
by Ewa Stawowczyk & Paweł Kawalec - 435-449 Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review
by Dolly Han & Nicolas Iragorri & Fiona Clement & Diane Lorenzetti & Eldon Spackman - 451-465 Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index–9 Dimension (CHU-9D) Score for Economic Evaluation in Children
by Tosin Lambe & Emma Frew & Natalie J. Ives & Rebecca L. Woolley & Carole Cummins & Elizabeth A. Brettell & Emma N. Barsoum & Nicholas J. A. Webb - 467-475 The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017
by Chris Skedgel & Dominika Wranik & Min Hu - 477-493 Treatment Preferences in Germany Differ Among Apheresis Patients with Severe Hypercholesterolemia
by Axel C. Mühlbacher & Andrew Sadler & Franz-Werner Dippel & Christin Juhnke - 495-504 Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer
by Josh J. Carlson & Kangho Suh & Panos Orfanos & William Wong - 505-505 Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 507-507 Correction to: Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Clinical Excellence Single Technology Appraisal
by Irina A. Tikhonova & Tracey Jones-Hughes & James Dunham & Fiona C. Warren & Sophie Robinson & Peter Stephens & Martin Hoyle
March 2018, Volume 36, Issue 3
- 259-261 Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care
by Ya-Chen Tina Shih & Shelley Fuld Nasso & S. Yousuf Zafar - 263-284 Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions
by Paolo A. Cortesi & Lucia S. D’Angiolella & Alessandra Lafranconi & Mariangela Micale & Giancarlo Cesana & Lorenzo G. Mantovani - 285-288 Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Bram L. T. Ramaekers & Robert Wolff & Anoukh Giessen & Xavier Pouwels & Debra Fayter & Shona Lang & Nigel Armstrong & Gill Worthy & Steven Duffy & Jos Kleijnen & Manuela A. Joore - 289-299 Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Ahmed Abdulla & Adrian Bagust & Sophie Beale & Marty Richardson & Angela Stainthorpe & Angela Boland & Eleanor Kotas & Joanne McEntee & Daniel Palmer - 301-322 Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review
by Lazaros Andronis & Ilias Goranitis & Sue Bayliss & Rui Duarte - 323-340 Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review
by Peter Ghijben & Yuanyuan Gu & Emily Lancsar & Silva Zavarsek - 341-347 A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
by Shijie Ren & Jonathan Minton & Sophie Whyte & Nicholas R. Latimer & Matt Stevenson - 349-358 Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis
by Rebekah Fong Soe Khioe & Chris Skedgel & Andrew Hart & Michael Philip Nelson Lewis & Leo Alexandre - 359-368 Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
by Amr Makady & Ard Veelen & Páll Jonsson & Owen Moseley & Anne D’Andon & Anthonius Boer & Hans Hillege & Olaf Klungel & Wim Goettsch - 369-380 Sensitivity of the Medication Possession Ratio to Modelling Decisions in Large Claims Databases
by Margret V. Bjarnadottir & David Czerwinski & Eberechukwu Onukwugha - 381-382 Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 383-384 Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”
by Noga Gershon & Yakir Berchenko
February 2018, Volume 36, Issue 2
- 127-130 Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines
by Salah Ghabri & Irina Cleemput & Jean-Michel Josselin - 131-144 Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Matt Stevenson & Katy Cooper & Sue Harnan & Jean Hamilton & Mark Clowes & Christopher Carroll & Tim Harrison & Shironjit Saha - 145-159 Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Saskia Groot & Debra Fayter & Robert Wolff & Nigel Armstrong & Lisa Stirk & Gill Worthy & Fernando Albuquerque de Almeida & Jos Kleijnen & Maiwenn J. Al - 161-173 The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil
by Livia Lovato Pires de Lemos & Augusto Afonso Guerra Júnior & Marisa Santos & Carlos Magliano & Isabela Diniz & Kathiaja Souza & Ramon Gonçalves Pereira & Juliana Alvares & Brian Godman & Marion Bennie & Ivan Ricardo Zimmermann & Vânia Crisitna Canuto Santos & Clarice Alegre Pretramale & Francisco de Assis Acurcio - 175-187 Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review
by Mo Zhou & Winter Maxwell Thayer & John F. P. Bridges - 189-204 Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies
by Sergio Iannazzo & Ange-Christelle Iliza & Louise Perrault - 205-213 Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe
by Jonas Hermansson & Thomas Kahan - 215-223 Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study
by Yasuhiro Hagiwara & Takeru Shiroiwa & Kojiro Shimozuma & Takuya Kawahara & Yukari Uemura & Takanori Watanabe & Naruto Taira & Takashi Fukuda & Yasuo Ohashi & Hirofumi Mukai - 225-238 Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
by Madeleine T. King & Rosalie Viney & A. Simon Pickard & Donna Rowen & Neil K. Aaronson & John E. Brazier & David Cella & Daniel S. J. Costa & Peter M. Fayers & Georg Kemmler & Helen McTaggart-Cowen & Rebecca Mercieca-Bebber & Stuart Peacock & Deborah J. Street & Tracey A. Young & Richard Norman - 239-252 Estimating the Reference Incremental Cost-Effectiveness Ratio for the Australian Health System
by Laura Catherine Edney & Hossein Haji Ali Afzali & Terence Chai Cheng & Jonathan Karnon - 253-257 Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?
by Melina Dritsaki & Alastair Gray & Stavros Petrou & Susan Dutton & Sarah E. Lamb & Joanna C. Thorn
January 2018, Volume 36, Issue 1
- 1-3 Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water
by Mattias Neyt - 5-6 Value-Based Pricing: L’Enfant Terrible?
by Sarah Garner & Andrew Rintoul & Suzanne R. Hill - 7-15 Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment
by Jaclyn Beca & Don Husereau & Kelvin K. W. Chan & Neil Hawkins & Jeffrey S. Hoch - 17-27 Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review
by Alisha Monnette & Yichen Zhang & Hui Shao & Lizheng Shi - 29-38 Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Hazel Squires & Abdullah Pandor & Praveen Thokala & John W. Stevens & Eva Kaltenthaler & Mark Clowes & Robert Coleman & Lynda Wyld - 39-49 Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal
by Irina A. Tikhonova & Tracey Jones-Hughes & James Dunham & Fiona C. Warren & Sophie Robinson & Peter Stephens & Martin Hoyle - 51-66 The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal
by Emma McManus & Tracey Sach & Nick Levell - 67-78 Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis
by Samuel Herzog & Marian Shanahan & Peter Grimison & Anh Tran & Nicole Wong & Nicholas Lintzeris & John Simes & Martin Stockler & Rachael L. Morton - 79-90 Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework
by Natalie Carvalho & Mark Jit & Sarah Cox & Joanne Yoong & Raymond C. W. Hutubessy - 91-103 Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
by Amir Ansaripour & Carin A. Uyl-de Groot & W. Ken Redekop - 105-113 Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
by Thea Asselt & Bram Ramaekers & Isaac Corro Ramos & Manuela Joore & Maiwenn Al & Ivonne Lesman-Leegte & Maarten Postma & Pepijn Vemer & Talitha Feenstra - 115-126 Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
by Usha G. Mallya & Susan H. Boklage & Andrew Koren & Thomas E. Delea & C. Daniel Mullins
December 2017, Volume 35, Issue 12
- 1195-1209 Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature
by Hamzeh Albaba & Charles Lim & Natasha B. Leighl - 1211-1221 Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nasuh C. Büyükkaramikli & Hedwig M. Blommestein & Rob Riemsma & Nigel Armstrong & Fiona. J. Clay & Janine Ross & Gill Worthy & Johan Severens & Jos Kleijnen & Maiwenn J. Al - 1223-1236 Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence
by Jan Norum & Carsten Nieder - 1237-1255 Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice
by Rachel A. Elliott & Lukasz Tanajewski & Georgios Gkountouras & Anthony J. Avery & Nick Barber & Rajnikant Mehta & Matthew J. Boyd & Asam Latif & Antony Chuter & Justin Waring - 1257-1270 Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
by Eddie Gibson & Ian Koblbauer & Najida Begum & George Dranitsaris & Danny Liew & Phil McEwan & Amir Abbas Tahami Monfared & Yong Yuan & Ariadna Juarez-Garcia & David Tyas & Michael Lees - 1271-1285 The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications
by Alessandra Ferrario & Diāna Arāja & Tomasz Bochenek & Tarik Čatić & Dávid Dankó & Maria Dimitrova & Jurij Fürst & Ieva Greičiūtė-Kuprijanov & Iris Hoxha & Arianit Jakupi & Erki Laidmäe & Olga Löblová & Ileana Mardare & Vanda Markovic-Pekovic & Dmitry Meshkov & Tanja Novakovic & Guenka Petrova & Maciej Pomorski & Dominik Tomek & Luka Voncina & Alan Haycox & Panos Kanavos & Patricia Vella Bonanno & Brian Godman - 1287-1296 The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment
by Sabine Elisabeth Grimm & Mark Strong & Alan Brennan & Allan J. Wailoo - 1297-1310 Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety
by Mehdi Najafzadeh & Jorge A. Garces & Alejandra Maciel
November 2017, Volume 35, Issue 11
- 1111-1112 Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread?
by Jonathan Karnon & Hossein Hajiali Afzali - 1113-1121 Replicating Health Economic Models: Firm Foundations or a House of Cards?
by Inigo Bermejo & Paul Tappenden & Ji-Hee Youn - 1123-1140 A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
by Hannah E. Burton & Stephen A. Mitchell & Maureen Watt - 1141-1151 Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Iñigo Bermejo & Matt Stevenson & Rachel Archer & John W. Stevens & Edward Goka & Mark Clowes & David L. Scott & Adam Young - 1153-1165 The Indonesian EQ-5D-5L Value Set
by Fredrick Dermawan Purba & Joke A. M. Hunfeld & Aulia Iskandarsyah & Titi Sahidah Fitriana & Sawitri Supardi Sadarjoen & Juan Manuel Ramos-Goñi & Jan Passchier & Jan J. V. Busschbach - 1167-1176 Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating
by Nicolas R. Thompson & Brittany R. Lapin & Irene L. Katzan - 1177-1185 Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer
by Laura McCullagh & Susanne Schmitz & Michael Barry & Cathal Walsh - 1187-1188 Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”
by Emma McManus & Tracey Sach - 1189-1190 Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’
by Inigo Bermejo & Paul Tappenden & Ji-Hee Youn
October 2017, Volume 35, Issue 10
- 977-980 ICER’s Revised Value Assessment Framework for 2017–2019: A Critique
by Peter J. Neumann & Joshua T. Cohen - 981-987 Availability and Pricing New Medicines in Ireland: Reflections and Reform
by Paul K. Gorecki - 989-1006 Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment
by Syed Salleh & Praveen Thokala & Alan Brennan & Ruby Hughes & Simon Dixon - 1007-1033 Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology
by Mohamed El Alili & Johanna M. Dongen & Judith A. F. Huirne & Maurits W. Tulder & Judith E. Bosmans - 1035-1046 Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
by Nigel Fleeman & Adrian Bagust & Angela Boland & Sophie Beale & Marty Richardson & Ashma Krishan & Angela Stainthorpe & Ahmed Abdulla & Eleanor Kotas & Lindsay Banks & Miranda Payne - 1047-1062 Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis
by Steven Simoens & Ira Jacobs & Robert Popovian & Leah Isakov & Lesley G. Shane - 1063-1072 Performance-Based Risk-Sharing Arrangements: An Updated International Review
by Josh J. Carlson & Shuxian Chen & Louis P. Garrison - 1073-1085 Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis
by Eric Jutkowitz & Fernando Alarid-Escudero & Hyon K. Choi & Karen M. Kuntz & Hawre Jalal - 1087-1101 Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008–2012
by Abaigeal D. Jackson & Andrew L. Jackson & Godfrey Fletcher & Gerardine Doyle & Mary Harrington & Shijun Zhou & Fiona Cullinane & Charles Gallagher & Edward McKone - 1103-1109 Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code
by Jörgen Möller & Sarah Davis & Matt Stevenson & J. Jaime Caro